{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Opdualag"},{"type":"Synonym","name":"nivolumab-relatlimab-rmbw"},{"type":"Synonym","name":"nivolumab/relatlimab-rmbw injectable formulation"},{"type":"Synonym","name":"relatlimab-rmbw/nivolumab"},{"type":"Synonym","name":"relatlimab-rmbw-nivolumab"},{"type":"Synonym","name":"relatlimab-rmbw and nivolumab"},{"type":"Synonym","name":"Opdivo/relatlimab-rmbw"},{"type":"CodeName","name":"BMS 986213"},{"type":"CodeName","name":"BMS-986213"},{"type":"CodeName","name":"BMS986213"},{"type":"Synonym","name":"nivolumab and relatlimab-rmbw"},{"type":"Synonym","name":"nivolumab and relatlimab"}],"definition":{"html":"An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","text":"An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-relatlimab-rmbw","text":"Nivolumab and Relatlimab-rmbw"},"nciConceptId":"C186440","nciConceptName":"Nivolumab/Relatlimab-rmbw","termId":809169,"name":"nivolumab/relatlimab-rmbw","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nivolumab-relatlimab-rmbw"},{"aliases":[{"type":"CodeName","name":"BMS-986016"},{"type":"Synonym","name":"anti-LAG-3 monoclonal antibody BMS-986016"},{"type":"CodeName","name":"BMS986016"}],"definition":{"html":"A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.\n","text":"A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C111999","nciConceptName":"Relatlimab","termId":754229,"name":"relatlimab","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"relatlimab"}],"links":null}